# Evaluating Subjective Well-being in Schizophrenic Patients Treated With quetiapineXR® and Other Atypical Antipsychotics

> **NCT00689325** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 158 (actual)

## Conditions studied

- Schizophrenia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT00689325
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 158 (ACTUAL)
- **Last updated:** 2010-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00689325

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00689325, "Evaluating Subjective Well-being in Schizophrenic Patients Treated With quetiapineXR® and Other Atypical Antipsychotics". Retrieved via AI Analytics 2026-08-18 from https://api.ai-analytics.org/clinical/NCT00689325. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*